{
    "clinical_study": {
        "@rank": "3326", 
        "arm_group": {
            "arm_group_label": "tDCS", 
            "arm_group_type": "Experimental", 
            "description": "tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks."
        }, 
        "brief_summary": {
            "textblock": "This research will help us to understand whether transcranial direct current stimulation\n      (tDCS) can safely improve recovery of speech and language abilities, gait , and mood in\n      people with Parkinson's disease and related disorders. Some of the disorders that will be\n      studied to understand if tDCS can be useful include Parkinson's Disease, Multi-System\n      Atrophy (MSA) and progressive supranuclear palsy (PSP)."
        }, 
        "brief_title": "Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood", 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Parkinson's disease or a related disorder (e.g. Multiple Systems Atrophy) as\n             diagnosed by a neurologist specializing in Movement Disorders\n\n          -  Age >= 18 years\n\n        Exclusion Criteria:\n\n          -  Skull defect at or near site of tDCS delivery.\n\n          -  History of a significant stroke or traumatic brain injury.\n\n          -  History of other brain conditions that could impact interpretation of results (such\n             as MS, brain tumor, encephalitis).\n\n          -  Presence of implanted electrical or metallic devices in the head or body (examples\n             include cardiac pacemakers or defibrillators, Baclofen pumps, deep brain stimulators,\n             ventricular shunts with metallic parts, vagus nerve stimulators)\n\n          -  Presence of ferrous metal in the head (except titanium; for instance shrapnel)\n\n          -  History of psychiatric disease requiring hospitalization, electroconvulsive therapy,\n             or ongoing medication use (other than common antidepressants)\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "id_info": {
            "nct_id": "NCT02104401", 
            "org_study_id": "00000"
        }, 
        "intervention": {
            "arm_group_label": "tDCS", 
            "description": "tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.", 
            "intervention_name": "tDCS", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "contact": {
                "email": "fpogan01@gunet.georgetown.edu", 
                "last_name": "Fernando Pagan, MD", 
                "phone": "202-444-1382"
            }, 
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20007"
                }, 
                "name": "MedStar Georgetown University Hospital"
            }, 
            "investigator": {
                "last_name": "Fernando Pagan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study: Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood", 
        "overall_contact": {
            "email": "fpogan01@gunet.georgetown.edu", 
            "last_name": "Fernando Pagan, MD", 
            "phone": "202-444-1382"
        }, 
        "overall_official": {
            "affiliation": "Georgetown University", 
            "last_name": "Fernando Pagan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will perform an assessment of motor function using Part III of the Unified Parkinson's Disease Rating Scale (UPDRS), timed test of gait, and patient self-assessment. Speech functions will be assessed with sentence repetition,evaluation of spontaneous speech, and other standard language tests. The assessment will also include other measures and questionnaires (e.g. Bech Depression Inventory) to be filled out by the patient and his/her family.", 
            "measure": "Improvement of Motor and Speech Symptoms of Parkinson's Disease or Related Disorders", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104401"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Improvement of Neuropsychiatric Symptoms of Parkinson's Disease or Related Disorders", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "source": "Georgetown University", 
        "sponsors": {
            "collaborator": {
                "agency": "Ferrell Family Charitable Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Georgetown University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}